Case 1: An 11-year-old male child presented with eczematous skin lesions since the age of 2 years on sun exposed parts, watering of eyes for 1 year and poor vision. He had appropriate neurodevelopment until 3-4 years of age and gradually developed dysarthria, cognitive impairment, behavioral abnormalities and crouching gait.On examination, he had pallor, short stature, bilaterally hazy cornea, lentigenes [ Figure 1a ], bilateral foot drop leading to pes cavus, cerebellar dysarthia and crouching gait. Nerve conduction study was suggestive of an axonal demyelinating (predominantly axonal) neuropathy of both lower extremities. His brainstem evoked response audiometry was normal. Skin biopsy was not done as there was no suspected premalignant or malignant lesion (actinic keratosis or early basal cell carcinoma/squamous cell carcinoma).
Case 2: The 14-year-old elder sister of case-1 presented with similar clinical features.
Case3: Youngest sibling of case-1 was an 8-year-old female child who presented with skin lesions and diminution of vision since last 2.5 years but had no neurological abnormality yet.
Pedigree analysis is presented in Figure 1b . None of the three siblings had any skin or ocular carcinoma but two of them manifested with axonal neuropathies. Corneal opacity and skin lesions improved by avoiding sun exposure, using ultraviolet preventing goggles, and sunscreen lotions on follow up.
On Target gene sequencing, two heterozygous variations in the ERCC2 gene were detected in all the three siblings [ Figure 1c] . A heterozygous missense variation in exon 8 of the ERCC2 gene (chr19:45867700) that results in the amino acid substitution of Asparagine for Aspartic acid at codon 234 (p.D234N; ENST00000391945) and a heterozygous missense variation in exon 21 of the ERCC2 gene (chr19:45855768) that results in the amino acid substitution of Glycine for Aspartic acid at codon 681 (p.D681G; ENST00000391945) was detected. The parents were heterozygous for one variant each. Both variants were also extensively analyzed for pathogenicity and analysis revealed the variants are predicted to be probably damaging by PolyPhen-2 and damaging by SIFT, LRT and Mutation Taster.
Absence of skin and eye cancer in our patients even at age of 14 years made us think whether a novel mutation in ERCC2 gene produces a noncancerous phenotype of XP. There is one case report from Japan of such mild presentation with other novel mutation in ERCC2. 4 Mutations in the human XPD helicase gene are mainly single residue changes; yet they cause three strikingly different genetic disorders: XP, XP/CS (cockayne syndrome), and trichothiodystrophy (TTD). Although all three diseases share a photo-sensitivity phenotype, they differ greatly in their predispositions to cancer or accelerated aging. XP patients show several thousand-fold increase in skin cancer, whereas neither CS nor TTD patients shows an increase in the cancer incidence despite photosensitivity. Furthermore, both CS and TTD are premature aging diseases plus developmental disorders. 5 A previous paper reporting a patient with compound heterozygous variant with D681N suggests the variant might cause less severe manifestations of disease. 5 In general, each mutational change in the XPD gene is specific for a particular clinical phenotype. The aforementioned case report significantly contributes to the understanding of genotype phenotype correlations in children with XP not having ocular or dermatologic malignancies. In this perspective, it is very important to establish a genetic diagnosis in children with XP to exactly prognosticate these patients and do an accurate genetic counseling of these families. A longer follow-up is required before conclusively saying that this is a noncancerous variant of XP and these families should be followed up life-long to better understand the natural history of this novel genotype.
